GID BIO Completes Trial of Stromal Cells to Treat Knee OA

GID BIO completed a pivotal Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results.

The trial demonstrated a median 87% reduction in pain, stiffness and function with no serious or device-related...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0